4268

Novel Autotaxin Inhibitor Drug (XIIPHONATE) for Cancer and/or Asthma

Reich Reuven, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Hoffman Amnon, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Breuer Eli, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

 

Category

Life Sciences and Biotechnology   

Keywords

Cancer, Asthma, Inhibitor, Autotaxin

Current development stage

 Verified in several preclinical models

Our Innovation

A new approach to treat metastatic disease has been developed and verified in several preclinical models. This oral treatment, a novel small molecule, acts extracellularly and thereby prevents the metastatic spread. The new molecule has been successfully tested for Asthma models and will be further studied for its efficiency at in-vivo models for cancer.

Advantages

  • The new compounds’ activity is limited to the extracellular compartment, thus there is no intracellular activity (toxicity)
  • The activity of the new compound lasts at least 48 h following single oral administration
  • The compound has unique clinical potential as cancer and metastasis therapy.
  • Molecules of the type of the new compound s are potent inhibitors of extracellular enzymes that support tumor and metastatic growth

Technology

The novel compound targets zinc-dependent enzymes in the extracellular milieu involved in tumor dissemination:

  • Autotaxin (ATX) which generates lysophosphatidic acid (LPA).
  • Carbonic Anhydrases (CA) IX, XII which regulates extracellular pH
  • Matrix metalloproteinase (MMP) which regulates ECM degradation

Opportunity

Anti-metastasis therapy is an unmet need. In particular, there is no oral treatment to this clinical problem. We discovered a new approach to treat metastatic disease in that was verified in several preclinical models.

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608